Analysis

Mylan’s 3rd Circ. Doryx Loss A Hurdle To Product-Hop Suits

Law360, Fort Wayne (May 10, 2017, 2:19 PM EDT) -- Mylan won’t appeal an adverse Third Circuit ruling in an antitrust suit over acne treatment Doryx — and though the decision does not preclude product-hopping claims, it could make it harder for them to succeed, such as in the Suboxone case brought by more than 40 states in the same circuit.

Mylan Pharmaceuticals Inc. has allowed to lapse an April 28 deadline to file a petition for certiorari with the U.S. Supreme Court in the case, leaving in place a September Third Circuit decision finding that...
To view the full article, register now.